Cargando…

Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study

PURPOSE: Triple negative breast cancer (TNBC) is more common in African American (AA) than Non-AA (NAA) population. We hypothesize that tumor microenvironment (TME) contributes to this disparity. Here, we use multiplex quantitative immunofluorescence to characterize the expression of immunologic bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yaghoobi, Vesal, Moutafi, Myrto, Aung, Thazin Nwe, Pelekanou, Vasiliki, Yaghoubi, Sanam, Blenman, Kim, Ibrahim, Eiman, Vathiotis, Ioannis A., Shafi, Saba, Sharma, Anup, O’Meara, Tess, Fernandez, Aileen I., Pusztai, Lajos, Rimm, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670126/ https://www.ncbi.nlm.nih.gov/pubmed/34906209 http://dx.doi.org/10.1186/s13058-021-01493-w

Ejemplares similares

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
por: Marczyk, Michal, et al.
Publicado: (2022)

Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
por: Gavrielatou, Niki, et al.
Publicado: (2023)

Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
por: Aung, Thazin Nwe, et al.
Publicado: (2022)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer
por: Aung, Thazin N., et al.
Publicado: (2023)

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer
por: MacNeil, Tyler, et al.
Publicado: (2021)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2021)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade
por: Vathiotis, Ioannis A., et al.
Publicado: (2022)

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry
por: MacNeil, Tyler, et al.
Publicado: (2020)

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Spatial characterization and quantification of CD40 expression across cancer types
por: Bates, Katherine M., et al.
Publicado: (2023)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
por: Qing, Tao, et al.
Publicado: (2020)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action
por: Aung, Thazin Nwe, et al.
Publicado: (2017)

Tumor mutational burden as a predictor of immunotherapy response in breast cancer
por: O’Meara, Tess A., et al.
Publicado: (2021)

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2023)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Cell cycle, energy metabolism and DNA repair pathways in cancer cells are suppressed by Compound Kushen Injection
por: Cui, Jian, et al.
Publicado: (2019)

DeORFanizing Candida albicans Genes using Coexpression
por: O’Meara, Teresa R., et al.
Publicado: (2021)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

STING enhances cell death through regulation of reactive oxygen species and DNA damage
por: Hayman, Thomas J., et al.
Publicado: (2021)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Understanding the Mechanistic Contribution of Herbal Extracts in Compound Kushen Injection With Transcriptome Analysis
por: Shen, Hanyuan, et al.
Publicado: (2019)

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms
por: Cui, Jian, et al.
Publicado: (2020)

A New Strategy for Identifying Mechanisms of Drug-drug Interaction Using Transcriptome Analysis: Compound Kushen Injection as a Proof of Principle
por: Shen, Hanyuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_809k10k0ajt1c4t02g6omlb060